{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:20:41Z","timestamp":1761675641376},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0004423","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:01:00Z","timestamp":1234224060000},"page":"e4423","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia"],"prefix":"10.1371","volume":"4","author":[{"given":"Natalia L.","family":"Komarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen A.","family":"Katouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wodarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2009,2,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/asheducation-2003.1.132","article-title":"Chronic myeloid leukemia.","author":"JV Melo","year":"2003","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis.","volume":"103","author":"B Calabretta","year":"2004","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression.","volume":"16","author":"AS Shet","year":"2002","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1532\/IJH97.04032","article-title":"Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.","volume":"79","author":"C Yoshida","year":"2004","journal-title":"Int J Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"NP Shah","year":"2004","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/shem.2003.50035","article-title":"Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.","volume":"40","author":"GQ Daley","year":"2003","journal-title":"Semin Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib.","volume":"55","author":"MW Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.med.53.082901.103853","article-title":"Recent advancements in the treatment of chronic myelogenous leukemia.","volume":"53","author":"ME O'Dwyer","year":"2002","journal-title":"Annu Rev Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors.","volume":"3","author":"H Daub","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","first-page":"225","article-title":"Overcoming resistance to imatinib by combining targeted agents.","volume":"2","author":"BJ Druker","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies.","volume":"91","author":"BJ Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL.","volume":"11","author":"V Nardi","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1535-6108(02)00101-0","article-title":"Resistance in the land of molecular cancer therapeutics.","volume":"2","author":"KM Shannon","year":"2002","journal-title":"Cancer Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1073\/pnas.97.14.7681","article-title":"Production of resistant HIV mutants during antiretroviral therapy.","volume":"97","author":"RM Ribeiro","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: principles of emergence and prevention.","volume":"102","author":"NL Komarova","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"M Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.","volume":"108","author":"HA Bradeen","year":"2006","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exphem.2007.01.023","article-title":"Optimizing therapy of chronic myeloid leukemia.","volume":"35","author":"MW Deininger","year":"2007","journal-title":"Exp Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.","volume":"7","author":"E Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors.","volume":"6","author":"A Quintas-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0025-5564(83)90066-4","article-title":"A model for resistance of tumor cells to cancer chemotherapeutic agents.","volume":"65","author":"JH Goldie","year":"1983","journal-title":"Mathematical Biosciences"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511666544","article-title":"Drug resistance in cancer: mechanisms and models: Cambridge University Press.","author":"JH Goldie","year":"1998"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02459682","article-title":"A stochastic model for the origin and treatment of tumors containing drug-resistant cells.","volume":"48","author":"AJ Coldman","year":"1986","journal-title":"Bull Math Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-05-3153","article-title":"Cancer stem cells: an old idea\u2013a paradigm shift.","volume":"66","author":"MS Wicha","year":"2006","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells.","volume":"414","author":"T Reya","year":"2001","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"206a","DOI":"10.1182\/blood.V106.11.698.698","article-title":"Application of FAST\u2122 fragment-based lead discovery and structure-guided design to discovery of small molecule inhibitors of BCR-ABL tyrosine kinase active against the T315I imatinib-resistant mutant.","volume":"106","author":"SK Burley","year":"2005","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.","volume":"102","author":"TA Carter","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia.","volume":"249","author":"JV Melo","year":"2007","journal-title":"Cancer Lett"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.","volume":"10","author":"EA Harrington","year":"2004","journal-title":"Nat Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.","volume":"66","author":"MA Young","year":"2006","journal-title":"Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/1535-7163.MCT-07-0305","article-title":"IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.","volume":"7","author":"EA Duncan","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.","volume":"105","author":"T O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0004423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T15:27:48Z","timestamp":1589556468000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0004423"}},"subtitle":[],"editor":[{"given":"Cathal","family":"Seoighe","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,2,10]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0004423","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,10]]}}}